Best Options Strategy for CCCC
Looking for the best options strategy for C4 Therapeutics, Inc. (CCCC)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live CCCC option chain right now, and a simple map from your view on CCCC to the strategy that fits it. Model any of them in the calculator before you trade.
About CCCC
C4 Therapeutics, Inc. (CCCC) is a major company in Biotechnology. Options traders on CCCC tend to watch , since these can drive large moves in the share price.
About C4 Therapeutics, Inc.
C4 Therapeutics is a clinical-stage biotech company that focuses on developing drugs designed to degrade proteins that cause disease. The company's approach centers on a technology platform that can target and remove specific disease-causing proteins from cells. Cemsidomide, its most advanced candidate, is an oral drug that targets two proteins called IKZF1 and IKZF3 and has completed early-stage testing for multiple myeloma. C4 is also advancing CFT8919, an oral drug candidate for non-small cell lung cancer that selectively targets a mutated form of the epidermal growth factor receptor. Beyond oncology, the company has additional programs aimed at addressing inflammation and neurological diseases.
C4 generates value through its drug development pipeline and strategic partnerships with established pharmaceutical companies. Roche has collaborated with the company on multiple fronts, including development of degrader-antibody conjugates for cancer treatment, while partnerships with Betta Pharmaceuticals and Merck KGAA provide additional resources and market access for specific programs. The company operates as a preclinical and clinical-stage enterprise without approved products…
Today's top-scoring strategy for CCCC
Our engine ranks defined-risk strategies on the live CCCC chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $3 | $0.01 |
| Sell | 1× | PUT | $4 | $0.09 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $5 | $8 | $8 | $8 | $8 | $8 |
| $5 | $8 | $8 | $8 | $8 | $7 |
| $5 | $8 | $8 | $7 | $7 | $6 |
| $5 | $8 | $7 | $6 | $5 | $4 |
| $4 | $7 | $5 | $4 | $2 | $0 |
| $4 | $3 | $1 | −$1 | −$3 | −$5 |
| $4 | −$5 | −$7 | −$10 | −$12 | −$14 |
| $4 | −$20 | −$21 | −$23 | −$24 | −$26 |
| $4 | −$38 | −$39 | −$39 | −$40 | −$40 |
| $3 | −$58 | −$58 | −$57 | −$56 | −$56 |
| $3 | −$76 | −$74 | −$73 | −$71 | −$70 |
Illustrative example at CCCC's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
CCCC is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on CCCC currently price in about 32% implied volatility, versus roughly 63% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$0.41 (±10%) in CCCC by 2026-09-18 — a range of roughly $3.76 to $4.57. Strikes inside that band hold most of the premium and see most of the action.
Earnings & IV crush
CCCC's next earnings report is due around November 5, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $401M
- Beta (vs market)
- 2.95
- 52-week range
- $1.69–$5.17 (71% up the range)
- Short interest
- 21.7% of float · 5.8 days to cover
With 21.7% of CCCC's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for CCCC
Start with your outlook on CCCC, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while CCCC stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open CCCC in the free calculator →
Frequently asked questions
What is the best options strategy for CCCC?
It depends on your outlook. Bullish traders often use a long call or bull call spread on CCCC; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are CCCC options liquid enough to trade?
C4 Therapeutics, Inc. (CCCC) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade CCCC options?
Buying a single CCCC call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade CCCC or any security. Do your own research.
What does C4 Therapeutics, Inc. do?
C4 Therapeutics, Inc. (CCCC) operates in the Biotechnology industry. The "About C4 Therapeutics, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does C4 Therapeutics, Inc. pay a dividend?
We don't show a confirmed dividend yield for C4 Therapeutics, Inc. here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
When does C4 Therapeutics, Inc. next report earnings?
C4 Therapeutics, Inc.'s next earnings are expected around November 5, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Price trend
Tickers related to CCCC
Comparing CCCC with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 490 Arsenal Way, Suite120, Watertown, MA, 02472, United States
- Industry
- Biotechnology
- Employees
- 104
- CEO
- Mr. Andrew J. Hirsch M.B.A.
- Phone
- 617 231 0700
- Website
- www.c4therapeutics.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.